|
PMN
|
Acumenpharma reported year end results this morning. Interesting they have...
|
|
PMN
|
Clinical trials on average for 3 phases run 6-7 years, ACU193 started phase1...
|
|
PMN
|
Clinical trials on average for 3 phases run 6-7 years, ACU193 started phase1...
|
|
PMN
|
PR for more information or to schedule a meeting, please visit the...
|
|
PMN
|
Had a good laugh, effecting the share price i wish. No one is following this...
|
|
PMN
|
How much longer before Promis goes private? Will be able to produce a movie...
|
|
PMN
|
A feel good letter means nothing with this group. Eugene Williams and Elliot...
|
|
PMN
|
Yes, that 14million trading day on July 17/23 is not defendable by any means....
|
|
PMN
|
Gail did ok for herself , on board September 2022, salary for remainder of...
|
|
PMN
|
Early on arrival shut down Social Media, Company communications, old outdated...
|
|
PMN
|
Preferred Shares and Series 1 Preferred Shares The Preferred Shares of...
|
|
PMN
|
The Boston Group.
|
|
PMN
|
For sure if you back Roche up 6-7 years ago with Gantenermab Phase 1, but...
|
|
PMN
|
An Embarrassment to say moving forward, the IND delayed by what 5-6 months...
|
|
PMN
|
Easy answer about including Alzheimers patients in Phase 1, just have to look...
|
|
PMN
|
https://www.investors.com/news/technology/biotech-stocks-the-war-in...
|
|
PMN
|
Ganteneuromab in the New England Journal posted today ! Two Phase 3 Trials...
|
|
PMN
|
Prothena states We are excited for initial topline results from our...
|
|
PMN
|
Yes Prothena Sad trial on PRX012 Phase 1 SAD Phase 1 Trial Design...
|
|
PMN
|
No meaniful news coming from them for probably quite some time. ACU 193 a one...
|